Skip to main content
TG THERAPEUTICS, INC. logo

TG THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · TGTX ISIN · US88322Q1085 LEI · 529900X21UKABN9NJ529 US Manufacturing
Filings indexed 1,011 across all filing types
Latest filing 2026-05-27 Regulatory Filings
Country US United States of America
Listing US TGTX

About TG THERAPEUTICS, INC.

https://www.tgtherapeutics.com/

TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company's primary area of focus is autoimmune diseases, particularly multiple sclerosis (MS). Its lead commercial product is BRIUMVI® (ublituximab), an approved therapy for adults with relapsing forms of MS. TG Therapeutics also develops a pipeline of potential therapies for B-cell malignancies and other autoimmune conditions, including investigational CAR-T cell therapies.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings
2026-05-27 English
8-K - TG THERAPEUTICS, INC. (0001001316) (Filer)
Regulatory Filings
2026-05-06 English
8-K - TG THERAPEUTICS, INC. (0001001316) (Filer)
Regulatory Filings
2026-03-20 English
10-K - TG THERAPEUTICS, INC. (0001001316) (Filer)
Annual Report FY 2025
2026-02-27 English
8-K - TG THERAPEUTICS, INC. (0001001316) (Filer)
Regulatory Filings
2026-02-26 English
4 Filing
Director's Dealing
2026-01-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.